Cargando…

Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2(pos) Breast Cancer

Although immune-based therapies have made remarkable inroads in cancer treatment, they usually must be combined with standard treatment modalities, including cytotoxic drugs, to achieve maximal clinical benefits. As immunotherapies are further advanced and refined, considerable efforts will be requi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghimirey, Nirmala, Steele, Chase, Czerniecki, Brian J., Koski, Gary K., Showalter, Loral E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062178/ https://www.ncbi.nlm.nih.gov/pubmed/33936816 http://dx.doi.org/10.1155/2021/8818393

Ejemplares similares

Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib
por: Showalter, Loral E., et al.
Publicado: (2019)

Murine Dendritic Cells Grown in Serum-Free Culture Show Potent Therapeutic Activity when Loaded with Novel Th Epitopes in an Orthotopic Model of HER2(pos) Breast Cancer
por: Showalter, Loral E., et al.
Publicado: (2021)

Statin Drugs Plus Th1 Cytokines Potentiate Apoptosis and Ras Delocalization in Human Breast Cancer Lines and Combine with Dendritic Cell-Based Immunotherapy to Suppress Tumor Growth in a Mouse Model of HER-2(pos) Disease
por: Oechsle, Crystal M., et al.
Publicado: (2020)

Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cells in vitro and suppress tumor growth in vivo
por: Showalter, Loral, et al.
Publicado: (2020)

T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells
por: Namjoshi, Prachi, et al.
Publicado: (2019)

Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway
por: Jia, Yongsheng, et al.
Publicado: (2021)

Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention
por: Nocera, Nadia F., et al.
Publicado: (2016)

Clinical development of immunotherapies for HER2(+) breast cancer: a review of HER2-directed monoclonal antibodies and beyond
por: Costa, Ricardo L. B., et al.
Publicado: (2020)

Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer
por: Lam, Lian, et al.
Publicado: (2014)

A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2(+) breast cancer
por: Costa, Ricardo, et al.
Publicado: (2019)

Oncodriver inhibition and CD4(+) Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies
por: Rosemblit, Cinthia, et al.
Publicado: (2018)

Evaluation of NMU-Induced Breast Cancer Treated with Sirolimus and Sunitinib on Breast Cancer Growth
por: Jaffar, Nurul Fathiyatul Nabila, et al.
Publicado: (2020)

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
por: Barrios, Carlos H., et al.
Publicado: (2010)

LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model
por: Rosenthal, Ken S., et al.
Publicado: (2017)

The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
por: Guti, Eliza, et al.
Publicado: (2022)

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer
por: Sparano, Joseph A., et al.
Publicado: (2022)

TRPA1 and TRPV1 contribute to propofol-mediated antagonism of U46619-induced constriction in murine coronary arteries
por: Sinharoy, Pritam, et al.
Publicado: (2017)

Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4(+) Th1 Responses and Potential Use as a Cancer Vaccine
por: Basu, Amrita, et al.
Publicado: (2022)

Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence
por: Wang, Denian, et al.
Publicado: (2020)

Preclinical Evaluation of (225)Ac-Labeled Single-Domain Antibody for the Treatment of HER2(pos) Cancer
por: Rodak, Magdalena, et al.
Publicado: (2022)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Target HER four in breast cancer?
por: Brockhoff, Gero
Publicado: (2019)

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
por: Keyvanjah, Kiana, et al.
Publicado: (2012)

Current State of Cell Therapies for Breast Cancer
por: Gautam, Namrata, et al.
Publicado: (2022)

Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer
por: Bloom, Meghan J., et al.
Publicado: (2020)

Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPV(POS) Cancers
por: Suksanpaisan, Lukkana, et al.
Publicado: (2018)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
por: Mills, Matthew N., et al.
Publicado: (2021)

An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer
por: Kozloff, M., et al.
Publicado: (2010)

HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model
por: Yin, Tao, et al.
Publicado: (2015)

Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma
por: Ramamoorthi, Ganesan, et al.
Publicado: (2022)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

Quantification of HER family receptors in breast cancer
por: Nuciforo, Paolo, et al.
Publicado: (2015)

Adjuvant therapy of HER2(+ )breast cancer
por: Winer, EP
Publicado: (2009)

Activating HER3 mutations in breast cancer
por: Mishra, Rosalin, et al.
Publicado: (2018)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

TH1 and TH2 cytokine data in insulin secretagogues users newly diagnosed with breast cancer
por: Wintrob, Zachary A.P., et al.
Publicado: (2017)

Intraoperative radiation therapy for breast cancer patients: current perspectives
por: Dutta, Sunil W, et al.
Publicado: (2017)

Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer
por: Yadav, Kritika, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_slqv7cbu3ee0462hqgpb2e5pnh